SEZanne
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- NCT07155174 ↗
- Recruiting
- AbbVie
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706; Atezolizumab; Etoposide; Carboplatin; Carboplatin; Lurbinectedin
- Arms
- Safety Lead-In: ABBV-706 Dose A · Experimental
- Safety Lead-In: ABBV-706 Dose B · Experimental
- Safety Lead-In: Stand of Care (SOC) · Experimental
- Expansion: ABBV-706 Dose A · Experimental
- Expansion: ABBV-706 Dose B · Experimental
- Expansion: SOC · Experimental
- Enrollment
- 180 (estimated)
- Primary outcomes
- Number of Participants with Adverse Events (AE)s
- Progression-Free Survival (PFS) Based on Investigator Assessment
- Sponsor
- AbbVie
- Start
- Nov 25, 2025
- Primary completion
- Apr 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07155174 · updated Oct 2, 2026